LABU250110P77000
- 0.05
- 0.000.00%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
Drugs Not Selected for Medicare Price Negotiation Nearly Doubled - Report
Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report
Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development
Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus
Assessing AbbVie: Insights From 17 Financial Analysts
Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies
8 Health Care Stocks Whale Activity In Today's Session
Moderna Analyst Ratings
Neurocrine Biosciences Analyst Ratings
Compugen Announced That The First Patient Was Dosed In A Phase 1 Clinical Trial With Com503, A Potential First-in-class Antibody Against Il-18 Binding Protein Licensed By Compugen To Gilead
AbbVie Analyst Ratings
Nvidia, Palantir, Ionq, Novavax, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
Arbutus Could Benefit From Big Pharma Bird Flu Vaccines: Jefferies
Stocks Sink As Bond Yields Soar, Nvidia Eyes Worst Day In 4 Months, Bitcoin Tumbles To $97,000: What's Driving Markets Tuesday?
Looking Into Gilead Sciences's Recent Short Interest
US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally
Moderna, Novavax and Other Vaccine Names Extend Gains Amid COVID/flu Concerns
Benzinga Market Summary: Bitcoin Falls, Vaccine Stocks Rise On Bird Flu Concerns, NVIDIA Drops
Shares of Vaccine Makers Are Trading Higher After the First Bird Flu Death Was Reporting in the US. Additionally, a Recent DCD Report Noted an Increase in Acute Respiratory Illness Activity.